drugset / Trial / NCT01723553

Amyloid-related Imaging Abnormalities (Microbleeds) in Atypical AD

NCT01723553

Phase 1 Completed 27 enrolled Mayo Clinic
NaSingle-groupOpen-labelDiagnostic

Summary

The study is designed to assess the demographic, clinical and imaging associations with the presence of microbleeds in atypical Alzheimer's disease. The primary hypothesis is that cognitive and functional performance will be poorer in atypical Alzheimer's subjects with microbleeds compared to those without microbleeds.

Timeline

Start
2012-11
Primary completion
2015-03
Completion
2015-03

Drugs

EvaluationDrugModalityDoseRoute
Subject C-11 PiB Diagnostic / imaging agent 740 mbq Intravenous